Zenith Drugs Ltd IPO
Open Demat Account
Zenith Drugs Ltd IPO Details
Details
| Total Shares Offered | Offer to Public | Retail Max (Shares) | Pre Issue Promoters Holding | Exchange | Issue size |
|---|---|---|---|---|---|
| ₹ 51.49 L | TBA | ₹ 15.04 L | ₹ 109.9 L | NSE | ₹ 40.68 Cr |
| IPO Open Date | Close Date | Lot Size | Min Investment | Issue Type | Listing Date |
| 19 Feb, 24 | 22 Feb, 24 | 1600 | ₹ 1,20,000 | Book Building - SME | 27 Feb, 24 |
Zenith Drugs Ltd IPO Dates
Details
| Sector | Type |
|---|---|
| Sector | Pharmaceuticals - Indian - Formulations |
| Sub Sector | NA |
| Issue Type | Book Building - SME |
Subscription Status
*Values are in Lakhs
| Investor Type | Subscription Times | Shares Offered* | Shares Bid* |
|---|---|---|---|
| QIB | 0x | 2147200 | 0 |
| NII | 9.25x | 644800 | 5961600 |
| Retail | 18.99x | 1504000 | 28558400 |
| Employee | 0x | 0 | 0 |
| Total | 7.29x | 5148800 | 37560000 |
Subscription Status
Investor Type
QIB
NII
Retail
Employee
Total
*Values are in Lakhs
Zenith Drugs Ltd Financial Status
Income Statement
Balance Sheet
| Particulars (in Rs. Crores) | FY23 | FY22 | FY21 |
|---|---|---|---|
| Revenue from operations | 131.62 | 114.52 | 91.66 |
| EBITDA | 15.89 | 9.26 | 7.08 |
| PAT | 9.54 | 4.88 | 3.21 |
| Total Assets | 112.90 | 84.08 | 53.84 |
| Share Capital | 17.15 | 0.40 | 0.40 |
| Total Borrowings | 14.21 | 13.87 | 16.70 |
| Operating Activities (Net Cash) | 10.84 | 6.18 | 4.55 |
| Investing Activities (Net Cash) | -3.88 | 0.03 | 0.03 |
| Financing Activities (Net Cash) | 14.21 | 13.87 | 16.70 |
| Net Cashflow | 8.74 | 0.20 | 2.89 |
Particulars (in Rs. Crores)
Revenue from operations
EBITDA
PAT
Total Assets
Share Capital
Total Borrowings
Operating Activities (Net Cash)
Investing Activities (Net Cash)
Financing Activities (Net Cash)
Net Cashflow
About Zenith Drugs Ltd
Zenith Drugs Limited was originally incorporated on November 15, 2000 as a Private Limited Company in the name of Zenith Drugs Private Limited under the provisions of the Companies Act, 1956 with the Registrar of Companies, Madhya Pradesh, Gwalior. Subsequently pursuant to a Special Resolution of the Shareholders passed in the Extra-Ordinary General Meeting held on September 05, 2023, the Company was converted from a Private Limited Company to Public Limited Company and consequently, the name of the Company was changed to `Zenith Drugs Limited' and a Fresh Certificate of Incorporation consequent to Conversion was issued on September 13, 2023 by the Registrar of Companies, Gwalior.
India is the largest provider of generic drugs globally and is known for its affordable vaccines and generic medications. The Indian Pharmaceutical industry is currently ranked third in pharmaceutical production by volume after evolving over time into a thriving industry growing at a CAGR of 9.43% since the past nine years. Generic drugs, over-the-counter medications, bulk drugs, vaccines, contract research & manufacturing, biosimilars, and biologics are some of the major segments of the Indian pharma industry. India has the most number of pharmaceutical manufacturing facilities that are in compliance with the US Food and Drug Administration (USFDA) and has 500 API producers that make for around 8% of the worldwide API market.
Zenith Drugs Limited is a reputable pharmaceutical manufacturing unit, dedicated to ensuring the highest quality standards. The Company is proud to be WHO-GMP compliant, adhering to the stringent guidelines set by the World Health Organization. Its commitment to quality is further demonstrated by its ISO 9001:2015 certification, obtained from a respected Euro-UK certification body. With a diverse portfolio of formulations, the company offers a wide range of medicines to meet the needs of patients.
Peer Comparison:
- Sudarshan Pharma Industries Ltd
- Sigachi Industries Ltd
Zenith Drugs Ltd IPO Key Points
Strengths
- Experienced Promoters and Management Team.
- Cost Efficiency.
- Formulation & Development.
- Regulatory Compliance.
- Global Reach.
Risk
- There are outstanding legal proceedings involving the Company, Promoters and Directors. Any adverse decision in such proceeding may have a material adverse effect on its business, results of operations and financial condition.
- Any manufacturing or quality control problems may disrupt its business operations, damage the company reputation for high quality production and expose it to potential litigation or other liabilities, which would negatively impact its business, prospects, cash flows, results of operations and financial condition.
- The company highly depends on its major raw materials and a few key suppliers who help it procure the same. the Company has not entered into long-term agreements with its suppliers for supply of raw materials. In the event the company is unable to procure adequate amounts of raw materials, at competitive prices its business, results of operations and financial condition may be adversely affected.
Strategy
- Increase by Targeting Unexplored Markets.
- Product Diversification.
- Formulations and Developments.
- Partnerships and Licensing Opportunities.
- Regulatory Compliance.
- Experienced Promoters and Management Team.
- Cost Efficiency.
- Formulation & Development.
- Regulatory Compliance.
- Global Reach.
How To Apply for Zenith Drugs Ltd IPO Online?
Step 1:
Log in to the BlinkX stock market app and click ‘IPO’ in the Xplore section.
Step 2:
From the list of open IPOs, select the IPO you want to invest.
Step 3:
Go through the IPO details like lot size, price band, about the company, etc.
Step 4:
Click ‘Apply IPO’ to apply and enter the number of lots and bidding price along with your UPI ID.
Step 5:
Confirm your bid and accept the payment mandate sent to your UPI App for completing the IPO application.